Cipla plans to make Cipmolnu® available at pharmacies and COVID treatment centers across the country. The approval follows a collaborative trial and a licensing agreement with Merck Sharpe Dohme for manufacturing and supply.
Cipla Limited has informed the Exchange regarding a press release dated December 28, 2021, titled "Cipla receives Emergency Use Authorisation (EUA) to launch oral anti-viral drug Cipmolnu�� (Molnupiravir 200 mg) in India to treat mild to moderate COVID-19 at high risk of developing severe disease".